Meltem TAŞBAKAN IŞIKGÖZ, Şebnem ŞENOL, ADNAN ŞİMŞİR, Hüsnü PULLUKÇU, Hasip KAHRAMAN, Oğuz Reşat SİPAHİ, Tansu YAMAZHAN, Bilgin ARDA, Erkan KISMALI, Alper TÜNGER, Sercan ULUSOY

Akut piyelonefritli 133 hastanın değerlendirilmesi

Akut piyelonefrit (APN), renal parankim ve toplayıcı sistemin bakteriyel veya fungal infeksiyonudur. Bu çalışmada, Ocak 2003-Mart 2011 tarihleri arasında kliniğimizde takip edilen APN olguları; komplike edici faktörler, klinik gidiş ve laboratuvar bulguları yönlerinden değerlendirilmiştir. Çalışma süresince 133 hastaya APN tanısı konmuştur (% 38 erkek, % 62 kadın, yaş ortalamaları 48.8±18.7 yıl). Yetmiş iki hasta (% 54) ilk kez APN geçirirken 61 hasta (% 46) yaşamları boyunca ortalama iki ve daha fazla APN atağı geçirmiştir. Hastaların % 25’inde komplike edici faktör saptanmazken; hastaların % 16’sında birden fazla komplike edici faktör bulunmuştur. En sık komplike edici faktörler obstrüktif üropati ve üriner kateterizasyon olarak belirlenmiştir. Bu çalışmada öyküsünde komplike edici faktör bulunmayan 45 (% 34) hastada batın ultrasonografisinde komplike edici faktör saptanmıştır. Sonuç olarak APN sık bir klinik durum olup, olgular olası komplike edici faktörler açısından değerlendirilmelidir.

Evaluation of 133 patients with acute pyelonephritis

Acute pyelonephritis (APN) is bacterial or fungal infection of the urinary tract or renal parenchyma. In this study, patients followed up between January 2003 and March 2011 with pyelonephritis were evaluated for laboratory findings, complicating factors and clinical outcome. During the study period there were 133 patients diagnosed with acute pyelonephritis (38 % male, 62 % female, aged 48.8±18.7 years). Seventy-two patients (54 %) had their first APN attack whereas 61 patients had their second or more episodes. There were no complicating factors in 25 % of patients however 16 % of patients had more than one complicating factor, and urinary catheterisation and obstructive uropathy were the most common complicating factors. In this series, complicating factors were detected by ultrasonography in 45 patients (34 %) who did not have such a medical history. In conclusion, APN is a common clinical entity and cases should be evaluated in terms of complicating factors.

PDF

___

1. Clinical and Laboratory Standards Institute. Performance Standards for Antimicrobial Susceptibility Testing. Fourteenth - Sixteenth Informational Supplement (M100-S16), CLSI, Wayne, PA (2004-2006).
2. Czaja CA, Scholes D, Hooton TM, Stamm WE. Population based epidemiologic analysis of acute pyelonephritis, Clin Infect Dis 2007;45(3):273-80. http://dx.doi.org/10.1086/519268 PMid:17599303
3. Doyuk KE, Ünlü F, Nayman AS, Özgüneş İ, Usluer G. Kliniğimizde izlenen komplike üst üriner sistem infeksiyonları, Flora 2006;11(4):181-7.
4. Foxman B. Epidemiology of urinary tract infections: incidence, morbidity, and economic costs, Am J Med 2002;113(1):5-13. http://dx.doi.org/10.1016/S0002-9343(02)01054-9
5. Foxman B, Klemstine KL, Brown PD. Acute pyelonephritis in US hospitals in 1997: hospitalization and in-hospital mortality, Ann Epidemiol 2003;13(2):144-50. http://dx.doi.org/10.1016/S1047-2797(02)00272-7
6. Hooton TM, Bradley SF, Cardenas DD et al. Diagnosis, prevention, and treatment of catheter-associated urinary tract infection in adults: 2009 International Clinical Practice Guidelines from the Infectious Diseases Society of America, Clin Infect Dis 2010;50(5):625-63. http://dx.doi.org/10.1086/650482 PMid:20175247
7. Karakeçili F, Karadağ S, Erbay F. Pyelonefrit: 190 olgunun retrospektif analizi, Klimik Derg 2010; 23(1):10-4.
8. Klausner HA, Brown P, Peterson J et al. A trial of levofloxacin 750 mg once daily for 5 days versus ciprofloxacin 400 mg and/or 500 mg twice daily for 10 days in the treatment of acute pyelonephritis, Curr Med Res Opin 2007;23(11):2637-45. http://dx.doi.org/10.1185/030079907X233340 PMid:17880755
9. Naber KG, Llorens L, Kaniga K, Kotey P, Hedrich D, Redman R. Intravenous doripenem at 500 milligrams versus levofloxacin at 250 milligrams, with an option to switch to oral therapy, for treatment of complicated lower urinary tract infection and pyelonephritis, Antimicrob Agents Chemother 2009;53(9):3782-92. http://dx.doi.org/10.1128/AAC.00837-08 PMid:19581455 PMCid:2737884
10. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing. 11th Informational Supplement. Document M100-S10, Vol. 21 No. 1, NCCLS, Wayne, PA (2001).
11. Nicolle LE, Friesen D, Harding GK, Roos LL. Hospitalization for acute pyelonephritis in Manitoba, Canada, during the period from 1989 to 1992; impact of diabetes, pregnancy, and aboriginal origin, Clin Infect Dis 1996;22(6):1051-6. http://dx.doi.org/10.1093/clinids/22.6.1051 PMid:8783709
12. Pullukçu H, Aydemir Ş, Taşbakan MI, Çilli F, Tunger A, Ulusoy S. Susceptibility of extended-spectrum beta-lactamase producing Esherichia coli urine isolates to fosfomycin, ciprofloxacin, amikacin and trimethoprim sulfamethoxazole, Turk J Med Sci 2008;38(2):175-80.
13. Pullukçu H, Taşbakan MI, Aydemir Ş ve ark. İdrar kültürlerinden soyutlanan bakteriler ve çeşitli antibiyotiklere in-vitro duyarlılıklarının değerlendirilmesi, ANKEM Derg 2006;20(1):26-30.
14. Ramakrishnan K, Scheid DC. Diagnosis and management of acute pyelonephritis in adults, Am Fam Physician 2005;71(5):933-42. PMid:15768623
15. Sipahi OR. Piyelonefrit, “Büke M (ed). Enfeksiyon Hastalıklarının Hasta Örnekleri ile Tanımı, 1. baskı’’ kitabında s:339-42, İzmir Güven Kitapevi, İzmir (2006).
16. Stunell H, Buckley O, Feeney J, Geoghegan T, Browne RF, Torreggiani WC. Imaging of acute pyelonephritis in the adult, Eur Radiol 2007;17(7): 1820-8. http://dx.doi.org/10.1007/s00330-006-0366-3 PMid:16937102
17. Talan DA, Stamm WE, Hooton TM et al. Compa-rison of ciprofloxacin (7 days) and trimethoprim-sulfamethoxazole (14 days) for acute uncomplicated pyelonephritis in women: a randomized trial, JAMA 2000;283(12):1583-90. http://dx.doi.org/10.1001/jama.283.12.1583
18. Tanyel E, Taşdelen FN, Tülek N, Leblebicioğlu H. Yaşlı hastalardaki üriner sistem infeksiyonlarının değerlendirilmesi, İnfeksiyon Derg 2006;20(2):87-91.
19. Tasbakan MI, Pullukçu P, Sipahi OR, Yamazhan T, Arda B, Ulusoy S. A pooled analysis of the resistance patterns of Escherichia coli strains isolated from urine cultures in Turkey: a comparison of the periods 1997-2001 and 2002-2007, Turk J Med Sci 2011;41(3):557-64.
20. Taşbakan MI, Pullukçu H, Yamazhan T, Arda B, Ulusoy S. Toplum kökenli üriner sistem infeksiyonlarından soyutlanan Escherichia coli suşlarına fosfomisinin in-vitro etkinliğinin diğer antibiyotiklerle karşılaştırılması, ANKEM Derg 2004;18(4): 216-9.
21. van Nieuwkoop C, van’t Wout JW, Spelt IC et al. Prospective cohort study of acute pyelonephritis in adults: safety of triage towards home based oral antimicrobial treatment, J Infect 2010;60(2):114-21. http://dx.doi.org/10.1016/j.jinf.2009.11.008 PMid:19945482
22. Warren JW, Abrutyn E, Hebel JR, Johnson JR, Schaeffer AJ, Stamm WE. Guidelines for antimicrobial treatment of uncomplicated acute bacterial cystitis and acute pyelonephritis in women. Infectious Diseases Society of America (IDSA), Clin Infect Dis 1999;29(4):745-58. http://dx.doi.org/10.1086/520427 PMid:10589881